ImmunisLogoWImmunisLogoImmunis Chairman Dr. Hans Keirstead Presents Keynote Address at the United Nations “AI for Good” Global SummitImmunis Chairman Dr. Hans Keirstead Presents Keynote Address at the United Nations “AI for Good” Global Summit
  • Home
  • About
  • Technology
  • Clinical Trials
  • News & Media
  • Contact
✕
Immunis Chairman Dr. Hans Keirstead Is Awarded Innovator of the Year [photo]
Immunis Welcomes Dr. Peter Diamandis to the Executive Advisory Board
Immunis Chairman Dr. Hans Keirstead Presents Keynote Address at the United Nations “AI for Good” Global Summit
IRVINE, Calif. — September 14, 2022 — Immunis, Inc., a private biotech company producing a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., delivered a keynote to the United Nations (UN) as part of the AI for Good Global Summit. AI for Good is a digital platform helping innovators become educated in building and identifying practical AI solutions for the advancement of the UN’s “Sustainable Development Goals.”

Dr. Keirstead, an internationally recognized stem cell expert and serial entrepreneur, was awarded this opportunity due to his success in biotech producing innovative treatments for spinal cord injury, cancer, immune disorders, motor neuron diseases, retinal diseases and a COVID-19 vaccine. In his address to the UN, Dr. Keirstead discusses the influence of AI on human healthcare and highlights how technology brings powerful resources that will advance patient treatment. The complete video of the address can be viewed here.

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages Immunis’ leading-edge capabilities in stem cell technologies to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ IMM01-STEM Phase 1/2a trial please visit: www.immunisbiomedical.com

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

###

Share

Recent News

  • Mar 10, 2023

    Immunis Chairman Dr. Hans Keirstead to Present at Abundance360

  • Mar 9, 2023

    Immunis Research Scientist Dr. Scott Greilach to Present at the Festival of Biologics in San Diego

  • Feb 27, 2023

    Immunis Chairman Dr. Hans Keirstead to Present at NextMed Health

Navigation

  • Home
  • About
  • Technology
  • Clinical Trials
  • News & Media
  • Contact

Contact info

Immunis, Inc.
Irvine, California


contact@immunisbiomedical.com

© 2022 Immunis, Inc. | All Rights Reserved